Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation
to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 739-742, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-922241
ABSTRACT
45.7% of Chinese patients with advanced lung adenocarcinoma were reported to harbour sensitizing epidermal growth factor receptor (EGFR) mutations. Limited therapeutic options are left for non-small cell lung cancer (NSCLC) harbouring sensitizing EGFR mutations after failure of EGFR-tyrosine kinase inhibitor (TKI) therapy and chemotherapy, finding effective options for them is an unmet clinic need. Herein we reported a case that till January 12, 2021, an 82-year-old female with sensitizing EGFR-mutant advanced lung adenocarcinoma received a surprising progression-free survival (PFS) benefit of over 21 months from the combination therapy of pembrolizumab and anlotinib after her failure of treatments of osimertinib, chemotherapy and anlotinib-monotherapy.
.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Quinolinas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Carcinoma de Pulmón de Células no Pequeñas
/
Anticuerpos Monoclonales Humanizados
/
Receptores ErbB
/
Adenocarcinoma del Pulmón
/
Indoles
/
Neoplasias Pulmonares
/
Mutación
Límite:
Anciano
/
Aged80
/
Femenino
/
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Lung Cancer
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS